Roth Capital Reiterates “Buy” Rating for Stemline Therapeutics Inc. (STML)
Stemline Therapeutics Inc. (NASDAQ:STML)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a report issued on Friday. They presently have a $32.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price objective indicates a potential upside of 153.97% from the company’s previous close.
Several other equities research analysts have also weighed in on STML. Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, August 5th. Zacks Investment Research upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Wednesday, October 5th. Finally, Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $20.50.
Stemline Therapeutics (NASDAQ:STML) opened at 12.60 on Friday. The company’s market capitalization is $224.60 million. Stemline Therapeutics has a 52 week low of $3.88 and a 52 week high of $14.20. The company’s 50-day moving average price is $11.71 and its 200 day moving average price is $8.52.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Stemline Therapeutics during the first quarter valued at approximately $232,000. Carl Domino Inc increased its position in shares of Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,000 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Stemline Therapeutics by 6.1% in the second quarter. California State Teachers Retirement System now owns 35,349 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 2,019 shares in the last quarter. Emerald Acquisition Ltd. acquired a new position in shares of Stemline Therapeutics during the second quarter valued at approximately $129,000. Finally, Nationwide Fund Advisors increased its position in shares of Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 8,670 shares in the last quarter. 53.21% of the stock is currently owned by institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.